docetaxel anhydrous has been researched along with 1-methyltryptophan in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (1-methyltryptophan) | Trials (1-methyltryptophan) | Recent Studies (post-2010) (1-methyltryptophan) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 145 | 4 | 121 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | 1-methyltryptophan (IC50) |
|---|---|---|---|
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 5.039 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN | 1 |
1 trial(s) available for docetaxel anhydrous and 1-methyltryptophan
| Article | Year |
|---|---|
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Florida; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tryptophan | 2014 |